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To assess the cumulative effect of an enhanced recovery after surgery (ERAS) pathway and a 
minimally invasive RARC with intracorporeal urinary diversion (iRARC) in comparison to open radical 
cystectomy (ORC) on hospital length of stay (LOS) and perioperative outcomes.  
 
Materials & methods  
Between Feb 2009 and Oct 2017, 304 radical cystectomy cases were performed at a single 
institution (54 ORC, 250 RARC). Data were prospectively collected. We identified 45 consecutive ORC 
cases performed without ERAS before the commencement of the RARC programme (Cohort A), 50 
consecutive iRARC cases performed without ERAS (Cohort B) and 40 iRARC cases with ERAS (Cohort 
C). Primary outcome measure was hospital LOS while secondary outcome measures included 
perioperative 90-day complications and readmission rates. Complications were accessed using the 
Clavian-Dindo classification.  
 
     
Results  
Patients in all cohorts were evenly match in age, sex, body mass index (BMI), neoadjuvant 
treatment, tumour stage, lymph node yield, previous pelvic radiotherapy and surgery, perioperative 
anaemia as well as physiological state. iRARC with ERAS patients had a significantly higher ASA (III-IV) 
and were more likely to receive neobladder reconstruction. Median hospital LOS were shorter in 
iRARC with ERAS (7 days, IQR: 6-10) compared to iRARC without ERAS (11, 8-15) and ORC (17 (14-
21). In a propensity score-matched cohort of iRARC patients, patients with ERAS has a significantly 
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significantly lower 90-day all (p<0.001) and GI related complications (p=0.001). the use of ERAS and 
younger patients were independently associated with a hospital LOS ≤10 days on multinomial 
logistic regression.  
 
Conclusion  
A comprehensive ERAS programme can significantly reduce hospital LOS in patients undergoing 
iRARC without increasing 90-day readmission rates. An ERAS programme can augment the benefits 
of iRARC in improving perioperative outcomes. In studies comparing ORC and RARC, the presence or 
absence of an ERAS programme will be a confounding factor and only level I evidence can be 
interpreted reliably.  
 
Introduction 
Radical cystectomy is the recommended treatment for muscle invasive bladder 
cancer and selected high risk non-muscle invasive bladder cancer as set out by 
international guidelines [1, 2]. Cystectomy is a morbid procedure and associated with 
a 3% 90-day mortality in high volume centers [3]. Risk of complication can be 
attributed to cardiovascular and respiratory comorbidity in an older population with a 
high prevalence of smoking history.  
Efforts to minimise postoperative morbidity include the development of robotic 
assisted radical cystectomy with intracorporeal urinary diversion (iRARC) and its 
rapid adoption seeks to replicate the oncological principles of open surgery whilst 
promoting early return to normal activity. Early oncological outcomes for open radical 
cystectomy (ORC) and iRARC are similar [4], however a meta-analysis of 
randomised controlled trials (RCT) comparing open ORC and RARC has failed to 
show significant differences in overall perioperative outcomes [5]. Although RARC 
results in lower blood loss and lower wound related complications, there was no 
difference in 90-day complications nor hospital length of stay (LOS). Single institution 
observation data does suggest a benefit for RARC however by definition, reports are 
from early adopters in high volume centres and frequently have established 
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ERAS was initially piloted and evolved for colorectal surgery and has led to the 
reduction in hospital LOS and complications without compromising patient safety [7]. 
More recently, ERAS has been implemented for radical cystectomy with reports of 
reduced perioperative complications rates and LOS to as low as four days [8-10]. 
ERAS represent a multi-modal perioperative care pathway designed to expedite 
postoperative recovery and improve morbidity by minimising organ dysfunction and 
reducing the metabolic stress response secondary to surgery.      
In this study, we assess the impact of iRARC as well as cumulative effect of ERAS 
and iRARC on the perioperative outcomes of patients undergoing radical 
cystectomy.  
   
Patient and methods  
Patient population 
Between March 2009 and November 2016, 304 radical cystectomy cases were 
performed at a single institution (54 ORC, 250 RARC). Data were prospectively 
collected using an institutional approved database. iRARC has been the default 
approach to radical cystectomy from 2014, with 98% of cystectomy cases performed 
by this approach. A structured ERAS pathway was adopted in May 2016. We 
identified 45 consecutive ORC cases without ERAS during which there was no 
iRARC performed (Cohort A), 50 consecutive iRARC cases before the 
implementation of an ERAS pathway (Cohort B) and 50 consecutive iRARC cases 
which were performed following the adoption of ERAS (Cohort C). All cases were 
performed by one of two surgeons. Fifty cases were excluded during the transition 
period from ORC to iRARC to account for iRARC learning curve and a further 75 
cases were excluded when the current ERAS pathway was gradually implemented 
(Figure 1). This study was part of a quality assurance programme and registered 
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Surgical technique  
All patients either received ileal conduit or neobladder reconstruction which was 
dependent on patient choice provided there were no absolute contraindications. A 
standard approach for ORC and iRARC has been previously described [11, 12]. A 
Studer neobladder was performed for ORC cases. Briefly, iRARC was performed 
using a standard 6-port transperitoneal approach with 20° Trendelenburg. A 
standard lymph node dissection template with the following boundaries were used 
for both open and iRARC cases: genitofemoral nerve laterally, ureteric crossing at 
the common iliac vessels proximally, the circumflex iliac vein and node of Cloquet 
anteriorly and the hypogastric vessels posteriorly. Following RARC and construction 
of urinary diversion, the specimen and dissected nodes were placed in an Endo 
Catch bag (Covidien, Dublin, Ireland) and removed. For patients receiving ileal 
conduit, a 15 cm segment of ileum 15 cm from the ileal-cecal valve was isolated 
using a 60 mm Endo-GIA laparoscopic intestinal stapler (Covidien, Dublin, Ireland). 
Intracorporeal neobladder construction was performed using 50 cm of terminal ileum, 
which was detubularised and cross-folded to form the Pyramid pouch, which is 
without an afferent limb [11]. A suprapubic and urethral catheter was placed for 
neobladder patients. Uretero-ileal anastomosis was performed using either Bricker or 
Wallace anastomosis depending on surgeon’s preference over 6 Fr infant feeding 
tubes. The tubes were externalised and sutured using 3-0 undyed polyglactin 910 
sutures (Ethicon, Somerville, New Jersey, USA), which breaks down after 10 days 
and allows the stents to fall out. A pelvic drain was placed and removed when output 
is <50 ml/ 24 hours. At six weeks, a cystogram was performed for neobladder 




All patients received best of care practice with no standardisation of preoperative 
and postoperative care. Patients abstained from food and only had clear fluids for 12 
hours, up until two hours before surgery. Bowel preparation was avoided prior to 
surgery. Intraoperatively, 3000 ml of intravenous (IV) fluids were typically prescribed 










This article is protected by copyright. All rights reserved. 
comprised of fentanyl patient controlled analgesia (PCA) stepping down onto an oral 
regime consistent with the World Health Organisation (WHO) analgesic stepladder. 
The ORC cohort had their nasogastric (NG) tube removed 1-2 days postoperatively 
provided they were tolerating oral intake. iRARC cohort had their NG tube removed 
following surgery. Patients were commenced on a soft diet from day two if tolerated. 
Patient mobilisation was dependent on the motivation of individual patients.  
 
Enhanced Recovery After Surgery (ERAS) 
The ERAS protocol implemented has been previously described [12]. All patients are 
seen at a dedicated cystectomy preassessment clinic where they see a surgeon, 
anaesthetist, stoma care nurse and have cardioplumonary exercise test (CPET) 
performed. Patients are educated on the surgical pathway and patient’s goals and 
expectations are set. 
No bowel prep is utilised, instead patients are advised to adopt a low-residue diet for 
two days prior to surgery. All patients are provided with two high calorie 
carbohydrate drinks to consume before surgery: one at 22:00 hours the night before 
surgery, the second at 06:00 hours on the day of surgery. Spinal anaesthesia with 2 
ml 0.5% heavy bupivacaine and 1 mg of diamorphine is used as a single shot 
neuroaxial block. A Transoesophageal Doppler is used for indirect monitoring of 
cardiac output to aid goal-directed fluid therapy.  
Following surgery, the NG tube is removed in theatre and all patients were admitted 
to intensive care. A standard prescribing regime includes paracetamol, non-steroidal 
and oral morphine for breakthrough pain as well as regular pharmacological agents 
to promote bowel recovery; metoclopramide, magnesium sulphate and ranitidine. 
Subcutaneous low molecular weight heparin is administered six hours following 
surgery for four weeks postoperatively.  
IV fluids are discontinued following surgery. Patients are commenced on oral clear 
fluids immediately postoperatively, and allowed free fluids orally as tolerated. Oral 
diet is started on the first postoperative day. Patients are instructed to start an 
incrementally increasing mobilisation regime starting with a minimum of 20 meters 
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Surgical, anaesthetic, nursing and physiotherapy staff assist patients with initial 
mobilisation and all teams empower the patient to independently follow the 
mobilisation regime thereafter.    
 
Data collected 
Patient demographics and preoperative variables including CPET which measures 
anaerobic threshold (AT), peak oxygen consumption (VO2) and minute ventilation/ 
carbon dioxide production (VE/VCO2) as well as American Association of 
Anaesthetics (ASA) score, clinical and pathological characteristics, were recorded. 
Peri- and post-operative data including perioperative 90-day complications, hospital 
LOS, readmission rates and mortality were collected. Postoperative ileus was 
confirmed on CT scan following clinical suspicion. All patients were followed-up for a 
minimum of 90-days following surgery.  
 
Study outcomes 
The primary endpoint was hospital LOS while the secondary endpoints for the study 
were 90-day readmission rate, and perioperative complications. Complications were 
classified using Clavian-Dindo classification.  
 
Statistics 
All continuous data such as mean, median, interquartile range and 95% confidence 
interval were reported using descriptive statistics. Comparative statistics between 
categorical variables were reported using Chi-square test, while t-test or ANOVA 
were used for comparison of continuous variables. Multivariable logistic regression 
was performed to determine the interaction between variables.  
To attempt to account for selection bias, propensity score-matched analysis was 
performed to adjust for differences in patient characteristics between iRARC treated 
patients with or without ERAS. The nearest neighbour propensity score-match was 
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was determined by modelling logistic regression with the following dependent 
variables: age, body mass index (BMI), gender, ASA score and neoadjuvant 
chemotherapy (NAC) use.   
SPSS v.22 (IBM Corp, Armonk, New York, USA) was used to perform all statistical 
analysis. Statistical significance was set a p value <0.05.    
 
Results  
Patient demographics for 45 ORC patients (Cohort A), 50 iRARC patients (Cohort B) 
and 50 iRARC patients with ERAS (Cohort C) are presented in Table 1. Patients in 
each cohort were evenly matched in age, gender, BMI, NAC, tumour stage, lymph 
node yield, previous pelvic radiotherapy and surgery, perioperative anaemia as well 
as physiological state (Table 1). iRARC patients with ERAS (Cohort C) had a 
significantly higher ASA (III-IV) and were more likely to receive neobladder 
reconstruction (Table 1).  
Table 2 presents data for hospital LOS, 90-day readmission rates, 90-day morbidity 
and mortality stratified by cohort. The overall 90-day readmission rate for all patients 
was 20%, and 90-day rate for all complication was 57.2% and 22.4% for major 
complications. GI related complications (37.9%) and infection (29.7%) were most 
common. Wound related complications were significantly less frequent in iRARC 
cases compared to ORC (5.0% vs 28.6%, p<0.001). 
An iRARC with ERAS (Cohort C) was associated with a reduced hospital LOS 
compared to ORC or iRARC alone (p<0.001) and with no associated increase in 
readmissions compared to Cohort A and B. Interestingly, the implementation of 
ERAS resulted in significantly lower 90-day all complications (p<0.001) and major 
complications (p=0.040). GI related complications were significantly lower in the 
ERAS patients treated with iRARC (18% vs 52%, p<0.001). The incidence of 
postoperative ileus was significantly lower in iRARC with ERAS patients (Cohort C) 
(16% vs 34%, p=0.021). There was no difference in 90-day infection and medical 
related complications. A box plot in Figure 2 shows the LOS distribution of the 










This article is protected by copyright. All rights reserved. 
Following propensity score-matching of iRARC patients to account for gender, age, 
BMI, ASA and neoadjuvant chemotherapy use, patients with ERAS were significantly 
associated with a lower 90-day admission rate (p=0.034) and all complications 
(p=0.006) and 30-day (p=0.017) and 90-day (p=0.002) GI related complications 
(Table 3). Patients with ERAS had a lower LOS (11.2 vs 14.0 days) although this 
was no significant.  
 
Multivariable regression confirms that the implementation of an ERAS pathway and 
lower patient age were independently associated with patient LOS ≤ 10 days (OR: 
0.2, 95% CI: 0.07-0.57, p=0.003) (Table 4). Additionally, multivariable regression 
show that ERAS was independently associated with associated with lower 90-day 
complications (OR: 0.17, 95% CI: 0.06-0.43, p<0.001) (Table 5).  
 
Discussion 
This study represents the first study to compare postoperative outcomes between 
patients who have undergone ORC and iRARC with or without an ERAS 
programme. We report that a structured ERAS protocol results in a decrease in 
hospital LOS in iRARC treated patients from a median of 11 to 7 days, without 
increasing 90-day readmission rates. In non-ERAS patients, there was a significantly 
shorter hospital LOS in iRARC compared to ORC, but it was the implementation of 
ERAS that augmented the benefits of iRARC and significantly improving 
perioperative outcomes. Furthermore, an ERAS protocol was independently 
associated with LOS < 10 days while a minimal invasive robotic approach was not.    
 
Historic reports of ORC performed at high-volume institutions reported a 58- 64% 90-
day complication rate following surgery, with a 13-22% major complication rate [13, 
14]. Previously, we reported a 90-day all and major complication rate of 72% and 
21% respectively with a median hospital LOS of 10.5 days in 134 consecutive 
iRARC cases {Tan, 2016 #159}. According to UK and USA population data, the 
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respectively [16, 17]. Evidence from the implementation of ERAS protocols in ORC 
have resulted in shorter LOS while complication and readmission rates have 
remained constant [8]. In this study, we observed similar findings in our iRARC 
patient cohort.  
Patient characteristics across our three patient cohorts were comparable. The only 
exception was that patients in Cohort C (iRARC with ERAS) where more likely to be 
ASA ≥III grade and undergo neobladder urinary diversion. Despite the potential 
disadvantage of increased anaesthetic risk, and more complex urinary diversion, 
patients in this cohort had a significantly lower hospital LOS compared to the non-
ERAS cohort of ORC and iRARC, which is testament of the advantages of an ERAS 
programme. The mean AT of 10.5 suggests that most patients treated had a poor 
physiological reserve, and that all patients regardless of co-morbidity would benefit 
from the implementation of an ERAS programme.  
In a propensity score-matched cohort of patients treated with iRARC adjusted for 
gender, age, BMI, ASA and NAC use, the introduction of ERAS reduced hospital 
LOS from a median of 11 to 7 days while significantly lowering the 90-day 
readmission rate suggests that patients were discharged home in a safe and timely 
manner. In addition, ERAS patients had a significantly lower rate of 90-day 
complications as well as a reduction in the incidence of ileus and subsequent GI 
related complications, which is recognised as a cause of prolonged hospital 
admission. The ERAS pathway, promotes early mobilisation, early introduction of 
oral intake, as well as the preference for non-steroidal analgesia over opiate based 
analgesia, all of which contribute towards early return to bowel function. As 
evidenced by data from an RCT, the adoption of spinal analgesia as part of an ERAS 
programme and avoiding epidural and PCA analgesia improves early mobilisation 
providing adequate pain control as well as the freedom from PCA pump attachment 
[18]. Epidural requires the continuous IV fluids which can lead to crystalloid overload 
resulting in oedematous bowel due to third spacing contributing to the developmental 
of ileus. Additionally, patients also mobilise less due to their attachment to IV lines.  
Not surprisingly ORC treated patients had significantly more wound complications 
compared to iRARC treated patients which is also consistent with data from meta-
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Our results are consistent with other reported outcomes following implementation of 
an ERAS pathway for RARC [9, 10, 19]. The median LOS of 7-8 days is reported 
and avoidance of PCA has been highlighted as a major factor influencing LOS. 
Although our preference is for spinal analgesia, the use of oxycodone is described 
by others [9, 10, 19]. The European Association of Urology Robotic Section Scientific 
Working Group recently published consensus for enhanced recovery for RARC in 
efforts to guide the standardisation of postoperative care [20].  
Previous studies have not reported 90-day complication rates, and instead report 30-
day all and major complication rate, ranging from 31- 57%, and 9-18% respectively, 
with a 30-day readmission rate of 3-33% (Table 6) [9, 10, 19]. In this series, we 
report a 90-day all and major complication rate of 42% and 12%, with a 12% 90-day 
readmission. Our reported 30-day complication and readmission rates are 
comparable to other reported series.    
We performed a multivariate analysis to identify factors which are associated with 
LOS ≤ 10 days. ASA ≥ III and elevated BMI as well as the technique of (open vs 
robotic) were not predictors of hospital LOS ≤ 10 days. In the iRARC + ERAS cohort, 
24% of patients had LOS > 10 days and this was associated with the development of 
30- and 90-day complications. We have previously reported that patients with 
significant risk factors such as preoperative anaemia, [21] and poor cardio-
respiratory reserve [22] are not an increased risk of developing complications 
following an iRARC procedure. We identified that age and ERAS are independently 
associated with a reduction in LOS.   
Within ERAS, there are multiple components which may influence the outcomes and 
can be considered as marginal gains representing small improvements in multiple 
areas that cumulatively result in significant benefit. As such, it is necessary to 
introduce the pathway as an all or nothing and our results suggest a significant gain. 
Similarly, the robotic approach has multiple components which collective can 
potentiate recovery however the impact of this alone has not been reported as level 
one evidence. 
There are important limitations in this study. Firstly, patient cohort size was limited 
and represents an evolution of an optimised cystectomy programme. While 
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cohort represents a historic cohort which was before centralisation of cystectomy 
services and the data collected were retrospective. It is worth noting that while ERAS 
was associated with the significant gains seen, other factors such as centralisation of 
services and learning curve may account for the decrease in morbidity reported. The 
ORC cohort was performed pre-centralisation and while the Pasadena Consensus 
suggest that the learning curve for RARC is around 30 cases, despite excluding our 
first 50 iRARC cases, surgical technical ability may continue to improve beyond this 
[23]. Due to the retrospective nature of the data on ORC cases 30-day readmission 
rate may be under represented. Interestingly, 15.6% (7/45 patients) of ORC patients 
had a LOS ≥30 days, compared to 6% (3/50 patients) and 4% (2/50 patients) in the 
iRARC and iRARC with ERAS patient cohorts.  
 
Conclusion 
In conclusion, this data suggests that ERAS is an independent factor associated with 
hospital LOS ≤ 10 days and that the surgical approach (iRACR or ORC) was not.  
However, patients receiving ORC had a significantly longer hospital LOS compared 
to iRARC alone or iRARC with ERAS. These results suggest that the impact of 
ERAS can be a confounding factor when interpreting surgical outcome reports 
following robotic surgery. The type of perioperative care pathway is likely to influence 
the postoperative recovery outcome data and may explain the variability between 
single center series and RCT data is essential when evaluating new surgical 
technology. A trial to compare robotic assisted radical cystectomy with open radical 
cystectomy (iROC, clinicaltrials.gov: NCT03049410) where patients are randomised 
to iRARC or ORC with a comprehensive institutional ERAS pathway is currently 
underway and results will be eagerly awaited.   
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Table 1: Patient characteristics  
 








Mean age, years (range) 65.0 (34.7-80.5) 62.8 (41.8-83.9) 66.2 (31.5-84.7) 0.327 
Sex, male (%) 32 (71.1) 36 (72.0) 40 (80.0) 0.467 
Mean body mass index (kg/m2) 
(range) 





























Preoperative anaemia (%) 24 (53.3) 24 (48.0) 24 (48.0) 0.838 
Prior pelvic radiotherapy (%) 1 (2.2) 2 (4.0) 1 (2.0) 0.936 
Prior pelvic surgery (%) 2 (4.4) 3 (6.0) 3 (6.0) 0.912 
CPET: 







Mean VO2Max (range)  16.6 (8-43) 15.4 (9-34) 0.348 
Mean VE/VCO2AT (range)  35.1 (27-49) 34.7 (26-51) 0.727 














Mean lymph node yield (range) 14 (0-48) 13 (0-35) 12 (0-26) 0.518 
Nodal metastasis (%) 6 (13.3) 12 (24.0) 5 (15.2) 0.356 
Diversion type (%) 
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Table 2: Details of patient length of stay, morbidity and mortality stratified according to 
patient cohort. 
 
 ORC (n=45) iRARC (n=50) iRARC+ERAS 
(n=50) 
P value 
Length of stay: 









Median, days (IQR) 17 (13.5, 21) 11 (7.8, 15.3) 7 (6-10.3)  
90-day mortality 3 (7.0) 3 (6.0) 1 (2.0) 0.502 
Postoperative ileus 14 (31.1) 19 (47.5) 8 (16.0) 0.047 
30-day readmission (%) 3 (6.7) 7 (14.0) 6 (12.0) 0.504 
90-day readmission (%) 10 (22.2) 13 (26.0) 6 (12.0) 0.107 
30-day all complications (%) 32 (74.4) 32 (64.0) 19 (38.0) 0.001 
30-day major complications (%) 11 (23.9) 11 (22.0) 6 (12.0) 0.354 
30-day GI complications (%) 19 (44.2) 23 (46.0) 11 (22.0) 0.023 
30-day infection complications (%) 17 (38.6) 13 (26.0) 11 (22.0) 0.182 
30-day wound complications (%) 10 (23.3) 0 (0) 1 (2.0) <0.001 
30-day medical complications (%) 14 (31.1) 10 (20.0) 7 (14.0) 0.064 
90-day all complications (%) 37 (86.0) 39 (78.0) 21 (42.0) <0.001 
90-day major complications (%) 13 (30.2) 13 (26.0) 6 (12.0) 0.040 
90-day GI complications (%) 20 (47.6) 26 (52.0) 9 (18.0) 0.001 
90-day infection complications (%) 16 (37.2) 17 (34.0) 10 (20.0) 0.148 
90-day wound complications (%) 12 (28.6) 3 (6.0) 2 (4.0) <0.001 












This article is protected by copyright. All rights reserved. 
Table 3: Details of patient length of stay, morbidity and mortality following propensity score 
matching to account for gender, age, BMI, ASA score and neoadjuvant chemotherapy use. 
 
 iRARC (n=40) iRARC+ERAS (n=40) P value 
Length of stay: 







Median, days (IQR) 10.5 (7.3-15) 7 (6-10)  
90-day mortality 1 (2.5) 1 (2.5) 0.986 
Postoperative ileus 14 (35.0) 7 (17.5) 0.075 
30-day readmission (%) 5 (12.5) 4 (10.0) 0.723 
90-day readmission (%) 10 (25.0) 3 (7.5) 0.034 
30-day all complications (%) 24 (60.0) 17 (42.5) 0.117 
30-day major complications (%) 7 (17.5) 6 (15.0) 0.762 
30-day GI complications (%) 18 (45.0) 8 (20.0) 0.017 
30-day infection complications (%) 11 (28.5) 10 (25.0) 0.799 
30-day wound complications (%) 0 (0) 1 (2.5) 0.314 
30-day medical complications (%) 6 (15.0) 7 (17.5) 0.762 
90-day all complications (%) 30 (75.0) 18 (45.0) 0.006 
90-day major complications (%) 8 (20.0) 5 (12.5) 0.363 
90-day GI complications (%) 20 (50.0) 7 (17.5) 0.002 
90-day infection complications (%) 15 (37.5) 9 (22.5) 0.143 
90-day wound complications (%) 3 (7.5) 2 (5.0) 0.644 
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Table 4: Multinomial logistic regression for LOS ≤ 10 days 
 
 P value OR (95% CI) 
ORC vs RARC 0.308 2.47 (0.43-14.12) 
Ileal conduit vs Neobladder 0.996 1.00 (0.23-4.34) 
Patient age (continuous) 0.014 1.1 (1.01-1.13) 
BMI (continuous) 0.948 1.00 (0.91-1.09) 
Preoperative anaemia (No vs Yes) 0.734 0.85 (0.32-2.24) 
ASA (I-II vs III-IV) 0.374 0.63 (0.23-1.75) 




Table 5: Multinomial logistic regression for 90-day all complications for patients treated with 
iRARC 
 
 90-day all complications 
 P value OR (95% CI) 
ORC vs RARC 0.369 0.16 (0.03-9.07) 
Ileal conduit vs Neobladder 0.409 1.71 (0.48-6.19) 
ASA (I-II vs III-IV) 0.141 2.07 (0.79-5.43) 
ERAS (No vs Yes) <0.001 0.17 (0.06-0.43) 
NAC (No vs Yes) 0.446 1.45 (0.54-3.90) 
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Miller et al. [9] Collins et al. 
[19] 
Number of ERAS cases 
and technique 
50 iRARC 102 iRARC 114 e/iRARC 135 iRARC 
Age, mean 66 68 67 70 
ASA ≥III, % 46 26  48 
Continent diversion, %  22 11 15 28 
Median LOS, days 7 8 7 8 
30-day complication, % 38 31 54 57 
30-day major 
complication, % 
12 9 18 19 
30-day readmission, %  12 3 18  
90-day complication, % 42    
90-day major 
complication, % 
12    
90-day readmission, % 12    
Key ERAS features  
No bowel prep Yes Yes  Yes  Yes 
Carbohydrate loading  Yes Not specified  Yes  Yes 
Goal directed IV fluids  Yes  Not specified  Yes Yes  
Spinal anaesthesia  Yes  Epidural Rectus sheath 
catheter +/- PCA 
Yes 
Remove NG tube 
immediately after 
surgery 
Yes  Not specified Yes Yes  
Drain use  Yes Not specified  No Yes 
Prokinetic agents  Yes  Yes Yes  Yes  
Chewing gum  Yes  Not specified  Not specified  Yes  
VTE prophylaxis  Yes Yes Yes Yes 
Early mobilisation  Yes  Yes  Yes Yes  
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